{"raw_mentions": "The compounds of this invention generally inhibit the aggregation of human platelets stimulated with ADP with IC50 of less than 0.1 uM.\nThe compounds of Examples 7, 22, 23 and 26 have IC50 of between 0.2 and 11 uM, and the compound of Example 4 had an IC50 of about 75 uM.\nPreferred compounds have IC50 of less than 0.04 uM."}
{"final_json": [{"molecule_name": "compounds of this invention", "protein_target_name": "human platelets", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<0.1", "unit": "uM"}, {"molecule_name": "compounds of Examples 7, 22, 23 and 26", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "0.2-11", "unit": "uM"}, {"molecule_name": "compound of Example 4", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "about 75", "unit": "uM"}, {"molecule_name": "Preferred compounds", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<0.04", "unit": "uM"}]}
